Voyager Therapeutics appoints George Scangos to Board of Directors

Voyager Therapeutics, Inc.

George Scangos, Ph.D., appointed as Class I director effective May 9, 2023, serving until 2025 annual meeting.
Scangos will serve on the Science and Technology Committee of the Board.
Compensation includes $40,000 annual cash retainer and initial option for 44,000 shares vesting over 4 years.
Scangos brings experience as former CEO of Biogen, Vir Biotechnology, and Exelixis.
He will enter standard indemnification agreement with Voyager.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

George Scangos

director

VYGR · Voyager Therapeutics, Inc.

Effective: 2023-05-09
Filed: May 9, 2023, 7:59 PM ET

On May 6, 2023, the Board of Directors (the “Board”) of Voyager Therapeutics, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed George Scangos, Ph.D. as a director of the Company and as a member of the Science and Technology Committee of the Board, effective May 9, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

George Scangos was appointed as director at Voyager Therapeutics, Inc..

Action: appointed
Role: director

Exact text from the filing

On May 6, 2023, the Board of Directors (the “Board”) of Voyager Therapeutics, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed George Scangos, Ph.D. as a director of the Company and as a member of the Science and Technology Committee of the Board, effective May 9, 2023.

View on SEC.gov

Voyager Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-057461

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.